Asia‑Pacific Governments Agree on a Coordinated Strategy to Secure Medical Radioisotope Supplies

At the inaugural Asia‑Pacific Medical Radioisotopes Workshop hosted by the Nuclear Energy Agency (NEA), senior policymakers, clinical specialists, industry leaders and regulators convened to devise shared solutions for mounting stresses on the nuclear medicine supply chain. Delegates prioritised practical, cross‑border measures to protect access to diagnostic and therapeutic radioisotopes as demand for PET imaging and targeted radionuclide therapies – including the expanding field of theranostics – rises across the region.

A staged regional framework: resilience now, capacity for the future

Participants endorsed a multi‑stage plan that combines immediate risk‑mitigation with medium‑ and long‑term capacity building. Key design principles were interoperability across national systems, redundancy to avoid single‑point failures, and streamlined movement for isotopes with short half‑lives so clinical services are not interrupted.

• Coordinated outage planning: member economies will publish synchronized maintenance schedules for major production facilities to avoid concurrent downtime.
• Priority travel lanes for time‑sensitive shipments: simplified customs and transport procedures targeted at tracers such as technetium‑99m and fluorine‑18.
• Shared technical standards: mutual acceptance of product specifications to enable rapid substitution during local shortages.
• Expanded regional training: pooled education and certification initiatives to grow the specialist workforce in radiopharmacy, medical physics and isotope production.

Pinpointing the weakest links: infrastructure, logistics and regulatory fragmentation

Workshop analysis highlighted a fragmented ecosystem: many production sites and radiopharmacies are decades old or running near capacity, distribution routes are often complex and transnational, and national regulatory frameworks vary. These factors increase the risk that a single failure can cause broad clinical disruption – notably for technetium‑99m (Tc‑99m), which underpins roughly 80% of conventional nuclear medicine scans and decays in about six hours, leaving little margin for transport delays.

• Limited surge capability: too few facilities can scale up quickly when reactors or cyclotrons are offline.
• Cold‑chain gaps: island and remote health services face challenges in refrigerated transport and on‑site storage.
• Fragmented situational awareness: no region‑wide, real‑time inventory view hinders rapid redistribution when shortages emerge.
• Workforce bottlenecks: insufficient numbers of radiopharmacists, maintenance engineers and regulatory specialists to support expansion.

Operational impacts and agreed remedies

• Problem: multiple national transport approvals → Impact: delayed deliveries for short‑lived tracers → Remedy: mutual recognition or single‑window clearance for medical isotope shipments.
• Problem: divergent labelling and inspection regimes → Impact: duplication, cost increases and slower handovers → Remedy: common baseline safety and labelling guidance coordinated by the NEA.
• Problem: opaque capacity data → Impact: poor contingency planning → Remedy: a shared digital registry showing production, storage and surge capability.

People, procedures and preparedness: the soft infrastructure that matters

Delegates stressed that technology investments will not suffice on their own; trained personnel and practised emergency protocols are equally essential. The workshop proposed regional training hubs, harmonised curricula, fellowship rotations and routine simulation exercises to build both capability and confidence. Practical operational measures under discussion include pre‑agreed supply corridors, formal trigger criteria to activate buffer stocks, and temporary regulatory flexibilities during declared crises.

• Standardised training pathways: curricula aligned to international safety standards to ease credential portability across borders.
• Cross‑functional skill development: programmes encouraging clinicians and technicians to acquire logistics and production skills for greater operational resilience.
• Regional emergency caches: prepositioned buffers and predefined redistribution agreements to be activated by clear thresholds.
• Multi‑country drills: tabletop and field exercises to validate protocols, communications and decision‑making under pressure.

Technical diversification: moving beyond a small number of production hubs

To reduce reliance on a handful of large reactors, workshop discussions highlighted alternative production pathways. Accelerator‑based production – including expanded cyclotron networks for PET tracers such as fluorine‑18 – offers a practical route to decentralise supply for imaging. Research reactors will continue to play a vital role for molybdenum‑99 (the parent of Tc‑99m) and for therapeutic nuclides like lutetium‑177 and iodine‑131, but complementary approaches increase resilience.

Across the Asia‑Pacific, several nations are already scaling local capabilities: hospital‑based cyclotrons are being deployed in metropolitan centres in countries such as South Korea and Australia to meet local PET demand, while India and China maintain reactor‑based production for export and domestic use. The rapid expansion of theranostics – pairing diagnostic scans with targeted radiotherapy – is shifting production priorities toward isotopes with longer shelf lives and tailored supply chains.

Concrete commitments, timelines and the NEA’s coordinating role

The meeting closed with a set of tangible actions and a request for the NEA to serve as a neutral technical secretariat. Agreed near‑term targets focus on building information systems, aligning transport rules and piloting regional skills initiatives.

• Within 6 months: launch a proof‑of‑concept digital registry mapping production sites, storage capacity and emergency inventories to enable rapid redistribution.
• Within 12 months: formalise a regional protocol for expedited cross‑border transit of short‑lived isotopes, including single‑window customs clearance pilots.
• Within 18-24 months: establish and operationalise at least two regional training hubs and execute a full‑scale, multi‑country supply‑chain simulation exercise.

The NEA has been asked to draft model guidance on mutual recognition of technical standards, coordinate data‑sharing templates, and host follow‑up workshops to track implementation progress.

Looking ahead: turning collaboration into measurable resilience

By bringing together governments, regulators, producers and clinical end users, the workshop created an action‑oriented blueprint to make medical radioisotope supply chains more robust. If the agreed measures are implemented – synchronised maintenance planning, transport streamlining, shared inventories, workforce development and technology diversification – the region can expect shorter outage response times, fewer patient disruptions and fairer access to life‑saving diagnostic and therapeutic isotopes across the Asia‑Pacific.